Shares of Exelixis (EXEL) gain 20% premarket after the firm announces positive top-line results from its Phase 3 clinical trail of cabozantinib in patients with medullary thyroid cancer. The company aims to build a cabozantinib franchise that includes large indications such as prostate cancer.
Shares of Exelixis (EXEL) gain 20% premarket after the firm announces positive top-line results...
From other sites
at CNBC.com (Dec 8, 2014)
at CNBC.com (Sep 29, 2014)
at CNBC.com (Sep 2, 2014)
at CNBC.com (Aug 6, 2014)
at CNBC.com (Jul 28, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs